Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Pharma Mar SA ( (ES:PHM) ).
Pharma Mar SA has entered into an exclusive license agreement with Merck for the development and commercialization of Zepzelca® (lurbinectedin) in Japan, targeting small cell lung cancer (SCLC). This collaboration will provide Pharma Mar with an initial payment of 22 million euros and potential additional earnings of up to 31 million euros through milestone achievements, while allowing Merck to leverage its market expertise to introduce the drug in Japan, expanding its availability to patients across Asia-Pacific regions.
More about Pharma Mar SA
Pharma Mar SA is a leading company in the research, development, and commercialization of marine-derived oncology therapies. The company focuses on innovative treatments for cancer, leveraging its expertise in marine biotechnology to develop novel therapeutic solutions.
YTD Price Performance: 4.44%
Average Trading Volume: 1,304
Technical Sentiment Signal: Sell
Current Market Cap: $1.58B
For a thorough assessment of PHM stock, go to TipRanks’ Stock Analysis page.